SINGLE-PHASE RETARDED ACID SYSTEMS USING AMINO ACIDS

Information

  • Patent Application
  • 20240271034
  • Publication Number
    20240271034
  • Date Filed
    September 23, 2022
    2 years ago
  • Date Published
    August 15, 2024
    4 months ago
Abstract
Treatment of hydrocarbon formations using single-phase aqueous acid blends that contain arginine is described herein. The single-phase aqueous fluid includes one or more strong acid molecules and arginine in water, wherein the one or more strong acid molecules are present in a concentration range of 7.5 wt % to 28 wt %, based on the weight of the aqueous fluid, and arginine is present in a molar ratio of arginine to the one or more strong acid molecules that is from 1:100 to 1:5.
Description
FIELD

This patent application describes methods and apparatus for stimulating hydrocarbon reservoirs. Specifically, methods and materials for acid treating hydrocarbon formations is described.


BACKGROUND

Almost two-thirds of the world's remaining oil reserves are contained in carbonate reservoirs. Carbonate formations have a tendency to be highly heterogeneous, with complex porosity and permeability variations, barriers, and irregular flow paths. In order to increase the productivity of wells in a calcareous formation, a range of stimulation techniques can be applied. One of the most common techniques involves the stimulation of a well with acids.


Acids can be injected into the formation to boost production or increase injectivity in oil and gas fields. Stimulation of carbonate rocks typically involves the reaction between an acid and the minerals calcite (CaCO3) and dolomite [CaMg(CO3)2] to enhance the flow properties of the rock. The reaction removes solid material from the rock structure into solution, creating openings in the rock formation for fluid flow.


Optimal acid treatment involves finding a balance between acid reacting too quickly with rock materials, thereby depleting before openings can be formed, and acid reacting too slowly, causing uniform dissolution of rock material, not the formation of openings. To manage the extremes, retarded acid systems are commonly used to extend reactivity of acid such that reactive acid can be delivered into the formation before being expended. One common type of retarded acid is emulsified acid, which is formed by suspending small acid droplets in a continuous hydrocarbon phase to form an emulsion. Emulsified acid can slow down the reaction rate between hydrochloric acid (HCl) and carbonate. However, emulsions typically have high viscosity and friction pressure, and are challenging to prepare at the wellsite. Single-phase retarded acid systems do not have the challenges of emulsions, but balancing the reactivity of the acid can be challenging. Single-phase acid systems also commonly result in flowback composition with low pH, for example, from a pH of 0 to 3, which can corrode equipment.


Improved single-phase retarded acid systems are needed for stimulation of carbonate reservoirs.


SUMMARY

Embodiments described herein provide a single-phase aqueous fluid that has one or more strong acid molecules and arginine in water, wherein the strong acid is present at a concentration in a range of 7.5 percentage by weight (wt %) to 28 wt %, based on the weight of the aqueous fluid, and arginine is present in a molar ratio of arginine to the strong acid that is from 1:100 to 1:5.


Other embodiments described herein provide a method of treating a subterranean formation penetrated by a wellbore by preparing a single-phase aqueous fluid having one or more strong acid molecules at a concentration in a range of 7.5 wt % to 28 wt % and arginine in range of concentration such that a molar ratio of arginine to acid is between 1:100 and 1:5 and contacting the subterranean formation with the single-phase aqueous fluid at a pressure less than the fracture initiation pressure.


Other embodiments described herein provide a method of treating a subterranean formation penetrated by a wellbore. The method includes obtaining a single-phase aqueous fluid comprising one or more strong acid molecules at a concentration in a range of 7.5 wt % to 28 wt % and an amino acid mixture, including arginine, in a range of concentration such that a molar ratio of amino acids to acid molecules is from 1:100 to 1:5, and contacting the subterranean formation with the single-phase aqueous fluid at a pressure less than the fracture initiation pressure.


Various refinements of the features noted above may be undertaken in relation to various aspects of the present disclosure. Further features may also be incorporated in these various aspects as well. These refinements and additional features may exist individually or in any combination. For instance, various features discussed below in relation to one or more of the illustrated embodiments may be incorporated into any of the above-described aspects of the present disclosure alone or in any combination. The brief summary presented above is intended to familiarize the reader with certain aspects and contexts of embodiments of the present disclosure without limitation to the claimed subject matter.





BRIEF DESCRIPTION OF THE DRAWINGS

Various aspects of this disclosure may be better understood upon reading the following detailed description and upon reference to the drawings, in which:



FIG. 1 is a graph showing rotating disc test results of aqueous fluids containing only HCl and L-arginine, in accordance with embodiments of the present disclosure;



FIG. 2 is a graph showing rotating disc test results of aqueous fluids containing HCl, L-arginine, and different surfactants, in accordance with embodiments of the present disclosure; and



FIG. 3 is a graph showing the pH effect of using arginine in an acid treatment fluid, in accordance with embodiments of the present disclosure.





DETAILED DESCRIPTION

One or more specific embodiments of the present disclosure will be described below. These described embodiments are only examples of the presently disclosed techniques. Additionally, in an effort to provide a concise description of these embodiments, all features of an actual implementation may not be described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.


When introducing elements of various embodiments of the present disclosure, the articles “a,” “an,” and “the” are intended to mean that there are one or more of the elements. The terms “comprising,” “including,” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements. Additionally, it should be understood that references to “one embodiment” or “an embodiment” of the present disclosure are not intended to be interpreted as excluding the existence of additional embodiments that also incorporate the recited features.


Blending one or more strong acid molecules with arginine in an aqueous fluid has been found to yield an acid system with reduced reactivity rate that is useful for acid treating acid-susceptible hydrocarbon reservoirs. Arginine is functional as an acid retardant for strong acid molecules such as hydrogen chloride (HCl, also called hydrochloric acid), hydrogen bromide in water (HBr, also called hydrobromic acid), hydrogen iodide (HI, also called hydroiodic acid), hydrogen fluoride in water (HF, also called hydrofluoric acid), sulfuric acid (H2SO4), nitric acid (HNO3), phosphoric acid (H3PO4), any alkanesulfonic acid (RSO3H, where R is an alkyl group), any arylsulfonic acid (ArSO3, where Ar is an aromatic or aryl group), or a combination thereof, in water solution. Because it is believed that the amino acid functionality of arginine provides acid retarding functionality, other amino acids, such as valine, serine, aspartate (also called aspartic acid), asparagine, glutamate (also called glutamic acid), glutamine, cysteine, and threonine can also be used in similar concentrations as arginine. Substituted versions of these amino acids can also be used. One or more substitutable hydrogen atoms on any of the above amino acids can be replaced by substituents, which may be, for example, aromatic or aliphatic organic groups such as phenyl groups, smaller alkyl groups, and/or smaller alkenyl groups. A mixture of the amino acids described above can also be used, where the mixture is present in these concentrations. One or more strong acid molecules and arginine (or another amino acid, or a mixture of amino acids), in water solution, form a single-phase aqueous fluid that can be used for acid treatment. The fluids described herein are retarded acid fluids that can be used to penetrate acid-susceptible formations for acid treatment, and provide flowback compositions that are less corrosive than conventional treatment fluids. For example, where conventional treatment fluids generally result in flowback at a pH of 0 to 3, the retarded acid fluids described herein generally provide flowback composition of pH from about 3 to about 5.5, resulting in reduced flowback time.


The strong acid molecule or molecules are generally present in the single-phase aqueous fluid at a concentration in a range of 7.5 wt % to 28 wt %, based on the weight of the single-phase aqueous fluid, and arginine is generally present in a molar ratio of arginine to the one or more strong acid molecules that is from 1:100 to 1:5, such as from 1:75 to 1:10, or from 1:70 to 1:15, for example about 1:47 or 1:19. In some cases, arginine is present in the single-phase aqueous fluid at a concentration of 10 wt %, or 5 wt %, or as low as 2 wt %.


Surfactants can also be used in acid-arginine blends to enhance acid retardation. Surfactants are generally used to modify surface properties of liquids. In the applications described herein, surfactants are generally believed to occupy sites where acid might react with acid-susceptible species in rock formations. Any surfactant that has affinity for acid-susceptible species in rock formations can be used. Such surfactants may be amphoteric, nonionic, cationic, or anionic. Surfactants that can be used include, but are not limited to, betaine-based materials such as erucic amidopropyl dimethyl betaine (EADB) and cocamidopropyl betaine (CAPB); alkyl ammonium bromide materials such as hexadecyltrimethyl ammonium bromide (CTAB, for cetyl trimethyl ammonium bromide) and tetradecyltrimethylammonium bromide (TTAB); and dodecylbenzene sulfonic acid. Combinations of surfactants can be used to tune the effect of acid and alcohol on the acid-susceptible species of the rock formation. The surfactant, or combination of surfactants, is generally added to a mixture of acid and alcohol to complete a single-phase treatment mixture.


Other components can be added to the single-phase acid mixtures described above for use in acid treatment of hydrocarbon formations. Such components include corrosion inhibitors, friction reducers, iron control reagents, diversion agents, viscosifiers, chelating reagents, solvents, clay stabilizers, and calcium inhibitors. These reagents can be added to the mixture neat or dissolved in water or another compatible solvent. For example, such reagents can be added to an alcohol to form a premix, and the premix can then be added to an acid solution to form a single-phase treatment mixture.


The single-phase aqueous mixtures described above can be used as acid treatment compositions with no further additional components, and can be used in a single-step acid treatment process, wherein the single-phase aqueous mixture consisting of water-miscible components and comprising one or more strong acid molecules, arginine (optionally mixed with other amino acids as described above), and a surfactant is pumped into a well to acidify the interior of a hydrocarbon formation adjacent to the well. Additional components can be added to the single-phase aqueous mixture to enhance the properties and performance thereof. Adding these components may result in a multi-phase mixture in some cases, or the mixture may remain single-phase after the additional components are added. Acid treatment mixtures described herein may also be used in multi-step processes that might include pre-treatment operations to flush the formation with flush compositions that may be liquid, gas, or a mixture thereof, and may be aqueous, oleaginous, or a mixture thereof. In some instances, a dilute acid flush may be used prior to acid treatment to remove any unwanted components from the formation prior to acid treatment.


Examples

To evaluate the performance of single-phase aqueous treatment fluids with strong acids and arginine, optionally including surfactants, mass loss rotating disk experiments were conducted. The mass loss experiments used a control fluid of 20 wt % HCl in water to compare to test fluids containing 20 wt % HCl and different concentrations of arginine and different surfactants. The mass loss experiments used marble discs of 1-inch diameter and ¼-inch thickness, with disc mass recorded every three minutes. Coreflow tests were also conducted using limestone cores.



FIG. 1 is a graph showing rotating disc test results of aqueous fluids containing only HCl and L-arginine (compared to an HCl solution). As seen in FIG. 1, adding arginine to a 20 wt % HCl solution results in slower dissolution of a marble disc, indicating acid retardation.



FIG. 2 is a graph showing rotating disc test results of aqueous fluids containing HCl, L-arginine, and different surfactants. As shown in FIG. 2, reaction rate of a solution of 20 wt % HCl and 5 wt % L-arginine is further retarded by including 1 wt % VES (viscoelastic surfactant). Also, in FIG. 2, a 20 wt % HCl solution containing 2 wt % L-arginine and 0.5 wt % TTAB reacts more slowly than the 5 wt % L-arginine solution with no surfactant.


Coreflow tests are summarized in Table 1. The coreflow test compared the performance of a 20 wt % HCl solution injected into 1-inch cores with performance of a 20 wt % HCl solution containing 10 wt % L-arginine and 1 wt % EADB injected into 1.5 inch cores. Table 1 indicates pore volume to breakthrough (PVBT), which is a volume of injection needed to create wormholes in the core.









TABLE 1







PVBT Values of Retarded and Control Acid Fluids








Acid System
PVBT











20 wt % HCl
8.3


Retarded acid (20 wt % HCl, 10 wt % L-arginine, 1 wt % EADB)
0.25









As shown in Table 1, much less (specifically about 90% less) acid treatment fluid volume is needed to create wormholes in the limestone cores using the retarded acid versus the control fluid.



FIG. 3 is a graph showing the pH effect of using arginine in an acid treatment fluid. As acid is spent in an acid treatment fluid, pH will rise at a rate that indicates how fast the acid is consumed. FIG. 3 compares adding carbonate to a 20 wt % HCl solution, as control, and to a 20 wt % HCl solution containing 2 wt % arginine. As shown in FIG. 3, pH rises quickly with the control fluid and slowly with the arginine-containing fluid, indicating retardation of acid reaction rate. Also notable from the data shown in FIG. 3 is the higher pH of the spent acid. Depending on the mass of calcite added, pH of the 2 wt % arginine solution is 1.5-2 units of pH higher than the arginine-free solution.


The specific embodiments described above have been illustrated by way of example, and it should be understood that these embodiments may be susceptible to various modifications and alternative forms. It should be further understood that the claims are not intended to be limited to the particular forms disclosed, but rather to cover all modifications, equivalents, and alternatives falling within the spirit and scope of this disclosure.

Claims
  • 1. A single-phase aqueous fluid comprising one or more strong acid molecules and arginine in water, wherein the one or more strong acid molecules are present at a concentration in a range of 7.5 wt % to 28 wt %, based on the weight of the aqueous fluid, and arginine is present in a molar ratio of arginine to the one or more strong acid molecules that is from 1:100 to 1:5.
  • 2. The single-phase aqueous fluid of claim 1, wherein the one or more strong acid molecules comprise hydrogen chloride.
  • 3. The single-phase aqueous fluid of claim 1, wherein the one or more strong acid molecules is hydrogen bromide, hydrogen iodide, hydrogen fluoride, sulfuric acid, nitric acid, phosphoric acid, an alkanesulfonic acid, or an arylsulfonic acid, or a combination thereof.
  • 4. The single-phase aqueous fluid of claim 1, further comprising a surfactant.
  • 5. The single-phase aqueous fluid of claim 4, wherein the surfactant is a viscoelastic surfactant.
  • 6. The single-phase aqueous fluid of claim 4, wherein the surfactant is a cationic surfactant.
  • 7. The single-phase aqueous fluid of claim 1, wherein arginine is present in the fluid at a concentration that is no more than about 2 wt %.
  • 8. The single-phase aqueous fluid of claim 1, wherein arginine is present in a molar ratio of arginine to the one or more strong acid molecules that is from 1:75 to 1:10.
  • 9. The single-phase aqueous fluid of claim 1, wherein arginine is present in a molar ratio of arginine to the one or more strong acid molecules that is from 1:70 to 1:15.
  • 10. A method of treating a subterranean formation penetrated by a wellbore, the method comprising: obtaining a single-phase aqueous fluid comprising: one or more strong acid molecules at a concentration in a range of 7.5 wt % to 28 wt %; andarginine in a range of concentration such that a molar ratio of arginine to acid molecules is from 1:100 to 1:5; andcontacting the subterranean formation with the single-phase aqueous fluid at a pressure less than the fracture initiation pressure.
  • 11. The method of claim 10, wherein the one or more strong acid molecules is hydrogen chloride.
  • 12. The method of claim 10, wherein the one or more strong acid molecules is hydrogen bromide, hydrogen iodide, hydrogen fluoride, sulfuric acid, nitric acid, phosphoric acid, an alkanesulfonic acid, or an arylsulfonic acid, or a combination thereof.
  • 13. The method of claim 10, wherein the single-phase aqueous fluid further comprises a surfactant.
  • 14. The method of claim 13, wherein the surfactant is a viscoelastic surfactant.
  • 15. The method of claim 13, wherein the surfactant is a cationic surfactant.
  • 16. The method of claim 10, wherein arginine is present in the single-phase aqueous fluid at a concentration that is no more than about 2 wt %.
  • 17. The method of claim 10, wherein arginine is present in the single-phase aqueous fluid at a concentration such that a molar ratio of arginine to the one or more strong acid molecules is from 1:75 to 1:10.
  • 18. The method of claim 10, wherein arginine is present in the single-phase aqueous fluid at a concentration such that a molar ratio of arginine to the one or more strong acid molecules is from 1:70 to 1:15.
  • 19. A method of treating a subterranean formation penetrated by a wellbore, the method comprising: preparing a single-phase aqueous fluid comprising: one or more strong acid molecules at a concentration in a range of 7.5 wt % to 28 wt % andan amino acid mixture in a range of concentration such that a molar ratio of amino acids to acid molecules is from 1:100 to 1:5, wherein the amino acid mixture comprises arginine; andcontacting the subterranean formation with the single-phase aqueous fluid at a pressure less than the fracture initiation pressure.
  • 20. The method of claim 19, wherein the single-phase aqueous fluid further comprises a surfactant.
CROSS-REFERENCE TO RELATED APPLICATION

This patent application claims benefit of U.S. Provisional Patent Application Ser. No. 63/248,223 filed Sep. 24, 2021, which is entirely incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2022/044553 9/23/2022 WO
Provisional Applications (1)
Number Date Country
63248223 Sep 2021 US